CD63 and cancer: In addition, to be potential candidates for cancer biomarkers, a recent study using immunohistochemistry (IHC) showed that tumor exosomal CD9 and CD63 might also act as potential prognostic monitors due to the increased expression in rectal tumor tissue after chemoradiation treatment (116).